BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, February 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 17, 2003
View Archived Issues
Rivastigmine reduces decline in daily activities in moderately severe AD
Read More
Prasterone prevents bone mineral loss in women with SLE
Read More
Hyperalgesic and analgesic effects of F-13640 following chronic dosing
Read More
Non-TZD PPAR modulator with potentially improved biological responses
Read More
Novel antimalarial artemisin derivatives claimed by Chinese research team
Read More
New CCR3 antagonists in early development at Bayer
Read More
Novel antiallergic agents discovered by Sumitomo researchers
Read More
Kaken presents new androgen receptor modulators
Read More
New erythromycin antibiotics prepared and tested by Hokuriku Seiyaku researchers
Read More
Novel 17beta-HSD type 3 inhibitors and their use in cancer and prostate disorders
Read More
Allergen-induced airway inflammation reduced by a caspase inhibitor in a murine model of asthma
Read More
Antipsychotic efficacy of a 5-HT2/dopamine D2 receptor antagonist shown in a murine model
Read More
FTC clears Pfizer's acquisition of Pharmacia
Read More
Elite develops opioid antagonist product to minimize abuse potential
Read More
GenVec and Diacrin to merge
Read More
Dyax and Alnis collaborate on therapeutic peptides for cancer
Read More
Certican demonstrates superiority to azathioprine in lung transplant patients
Read More
Patient enrollment completed in phase IIa trial of Onyvax-P
Read More
Canvaxin partial hold lifted, phase III enrollment to resume
Read More
Revimid granted fast track status for myelodysplastic syndromes
Read More
